• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Vaccine: Mechanism of Pathogenesis, Immune Evasion and Analysis of Vaccine Types.疫苗:发病机制、免疫逃逸及疫苗类型分析
Vaccines (Basel). 2025 May 15;13(5):526. doi: 10.3390/vaccines13050526.
2
Advances in Helicobacter pylori vaccine research: From candidate antigens to adjuvants-A review.幽门螺杆菌疫苗研究进展:从候选抗原到佐剂——综述。
Helicobacter. 2024 Jan-Feb;29(1):e13034. doi: 10.1111/hel.13034. Epub 2023 Nov 16.
3
Adjuvants for vaccines: Outer membrane vesicles provide an alternative strategy.疫苗佐剂:外膜囊泡提供了一种替代策略。
Virulence. 2024 Dec;15(1):2425773. doi: 10.1080/21505594.2024.2425773. Epub 2024 Nov 20.
4
: Routes of Infection, Antimicrobial Resistance, and Alternative Therapies as a Means to Develop Infection Control.感染途径、抗菌药物耐药性以及作为制定感染控制手段的替代疗法
Diseases. 2024 Dec 3;12(12):311. doi: 10.3390/diseases12120311.
5
Mucosal immunization with a urease B DNA vaccine induces innate and cellular immune responses against Helicobacter pylori.用尿素酶B DNA疫苗进行黏膜免疫可诱导针对幽门螺杆菌的固有免疫和细胞免疫反应。
Helicobacter. 2006 Apr;11(2):113-22. doi: 10.1111/j.1523-5378.2006.00385.x.
6
An intranasal influenza virus vector vaccine protects against in mice.鼻腔内流感病毒载体疫苗可预防 感染小鼠。
J Virol. 2024 Mar 19;98(3):e0192323. doi: 10.1128/jvi.01923-23. Epub 2024 Feb 15.
7
The design of vaccines against Helicobacter pylori and their development.抗幽门螺杆菌疫苗的设计及其研发。
Annu Rev Immunol. 2001;19:523-63. doi: 10.1146/annurev.immunol.19.1.523.
8
Perspectives from recent advances of Helicobacter pylori vaccines research.幽门螺杆菌疫苗研究最新进展的观点
Helicobacter. 2022 Dec;27(6):e12926. doi: 10.1111/hel.12926. Epub 2022 Sep 22.
9
Vaccinating against Helicobacter pylori infection.接种疫苗以预防幽门螺杆菌感染。
Nat Rev Gastroenterol Hepatol. 2011 Mar;8(3):133-40. doi: 10.1038/nrgastro.2011.1. Epub 2011 Feb 8.
10
Design of a multi-epitope vaccine based on immunoinformatics.基于免疫信息学的多表位疫苗设计。
Front Immunol. 2024 Aug 23;15:1432968. doi: 10.3389/fimmu.2024.1432968. eCollection 2024.

引用本文的文献

1
Co-Infection Dynamics of and Helminths: A Double-Edged Sword.与蠕虫的共同感染动态:一把双刃剑。 (你提供的原文中“Co-Infection Dynamics of and Helminths”存在信息缺失,推测完整原文可能是“Co-Infection Dynamics of Viruses and Helminths”,这里是按照推测完整后的内容翻译的,你可根据实际情况调整。)
Int J Mol Sci. 2025 Aug 19;26(16):8001. doi: 10.3390/ijms26168001.
2
Unraveling : Insights into Pathogenesis, Immune Evasion, and Progress Toward Effective Vaccination.解析:对发病机制、免疫逃逸及有效疫苗研发进展的洞察
Vaccines (Basel). 2025 Jul 3;13(7):725. doi: 10.3390/vaccines13070725.

本文引用的文献

1
A scoping review of worldwide guidelines for diagnosis and treatment of Helicobacter pylori infection.一项关于全球幽门螺杆菌感染诊断和治疗指南的范围综述。
Syst Rev. 2025 May 9;14(1):107. doi: 10.1186/s13643-025-02816-0.
2
infection process: from the molecular world to clinical treatment.感染过程:从分子世界到临床治疗
Front Microbiol. 2025 Feb 27;16:1541140. doi: 10.3389/fmicb.2025.1541140. eCollection 2025.
3
Immune Cell Crisis and Excess Histopathological Features During the Development and Progression of Infection in the Gastric Mucosa.胃黏膜感染发生发展过程中的免疫细胞危机及过多组织病理学特征
Int J Gen Med. 2025 Mar 6;18:1345-1357. doi: 10.2147/IJGM.S474925. eCollection 2025.
4
Global Population Structure, Virulence Factors and Antibiotic Resistance of Helicobacter pylori: A Pooled Analysis of 4067 Isolates From 76 Countries.幽门螺杆菌的全球种群结构、毒力因子及抗生素耐药性:来自76个国家4067株分离株的汇总分析
Helicobacter. 2025 Mar-Apr;30(2):e70025. doi: 10.1111/hel.70025.
5
Fucoidan-modified antibiotic-free nanovesicles: A multidimensional approach to eradicate intracellular and extracellular Helicobacter pylori and restore gastrointestinal homeostasis.岩藻依聚糖修饰的无抗生素纳米囊泡:根除细胞内和细胞外幽门螺杆菌并恢复胃肠道稳态的多维方法。
Int J Biol Macromol. 2025 May;307(Pt 2):141786. doi: 10.1016/j.ijbiomac.2025.141786. Epub 2025 Mar 7.
6
Long-term evaluation of Helicobacter pylori screening in school health checkups: an 11-year study in Japan.学校健康检查中幽门螺杆菌筛查的长期评估:日本一项为期11年的研究
J Gastroenterol. 2025 Jun;60(6):696-704. doi: 10.1007/s00535-025-02236-w. Epub 2025 Mar 7.
7
Genotypic diversity of the c region and its correlation with gastric disease outcomes.c区域的基因多样性及其与胃部疾病结局的相关性。
J Med Microbiol. 2025 Mar;74(3). doi: 10.1099/jmm.0.001969.
8
Association of related chronic atrophic gastritis and gastric cancer risk: a literature review.相关慢性萎缩性胃炎与胃癌风险的关联:一项文献综述
Front Med (Lausanne). 2025 Feb 20;12:1504749. doi: 10.3389/fmed.2025.1504749. eCollection 2025.
9
Nanomaterials in gastric cancer: pioneering precision medicine for diagnosis, therapy, and prevention.胃癌中的纳米材料:用于诊断、治疗和预防的开创性精准医学。
Med Oncol. 2025 Mar 6;42(4):93. doi: 10.1007/s12032-025-02650-3.
10
Expressions of selected microRNAs in gastric cancer patients and their association with Helicobacter pylori and its cag pathogenicity island.胃癌患者中所选 microRNA 的表达及其与幽门螺杆菌及其 cag 致病岛的关联。
Microb Pathog. 2025 May;202:107442. doi: 10.1016/j.micpath.2025.107442. Epub 2025 Mar 4.

疫苗:发病机制、免疫逃逸及疫苗类型分析

Vaccine: Mechanism of Pathogenesis, Immune Evasion and Analysis of Vaccine Types.

作者信息

Gong Jingwen, Wang Qing, Chen Xing, Lu Junhui

机构信息

The First Clinical Medical College, Shanxi Medical University, Taiyuan 030001, China.

Department of Gastroenterology, The First Hospital of Shanxi Medical University, Taiyuan 030001, China.

出版信息

Vaccines (Basel). 2025 May 15;13(5):526. doi: 10.3390/vaccines13050526.

DOI:10.3390/vaccines13050526
PMID:40432137
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12115874/
Abstract

is a gram-negative, spiral-shaped bacterium that colonizes the human gastric mucosa, leading to various gastric diseases. infection has become a pressing public health issue that affects more than 50% of the human population worldwide, almost 40 years after its discovery. Traditional treatments, based on the use of bismuth-based triple and quadruple therapies, are effective while facing a series of problems, such as difficulty in patient compliance, the rise of antibiotic resistance, and possible recurrence of infection. Therefore, the development of an efficacious vaccine against would be extremely urgent. This review mainly elaborates on the pathogenic mechanism and immune evasion mechanism of , as well as various strategies adopted in vaccine development, including whole-cell vaccines, subunit vaccines, DNA vaccines, and live vector vaccines. Animal studies and clinical trials demonstrate that vaccines significantly reduce bacterial load and provide cellular immunity over some time. Multiple studies have clarified the advantages and limitations of each candidate vaccine. Although the development of vaccines provides benefits to reduce the global burden, there are still significant challenges to developing vaccines in safety, efficacy, and availability. Overcoming these challenges, along with the advancement of vaccine technology, can better prevent and treat infection.

摘要

是一种革兰氏阴性螺旋形细菌,可定殖于人类胃黏膜,导致各种胃部疾病。幽门螺杆菌感染已成为一个紧迫的公共卫生问题,自其发现近40年后,全球超过50%的人口受到影响。基于铋剂三联和四联疗法的传统治疗方法虽有效,但面临一系列问题,如患者依从性差、抗生素耐药性上升以及感染可能复发等。因此,开发一种有效的抗幽门螺杆菌疫苗极为迫切。本综述主要阐述幽门螺杆菌的致病机制和免疫逃逸机制,以及疫苗开发中采用的各种策略,包括全细胞疫苗、亚单位疫苗、DNA疫苗和活载体疫苗。动物研究和临床试验表明,幽门螺杆菌疫苗可显著降低细菌载量,并在一段时间内提供细胞免疫。多项研究阐明了每种候选疫苗的优缺点。尽管幽门螺杆菌疫苗的开发有助于减轻全球负担,但在安全性、有效性和可及性方面开发疫苗仍面临重大挑战。克服这些挑战,随着疫苗技术的进步,能够更好地预防和治疗幽门螺杆菌感染。